We currently do not have sufficient information about the CEO.
Key information
Thomas O’Shaughnessy
Chief executive officer
CA$82.0k
Total compensation
CEO salary percentage
100.00%
CEO tenure
2yrs
CEO ownership
0.1%
Management average tenure
less than a year
Board average tenure
1yr
Recent management updates
Recent updates
CEO Compensation Analysis
How has Thomas O’Shaughnessy's remuneration changed compared to Onco-Innovations's earnings?
Date
Total Compensation
Salary
Company Earnings
Jan 31 2026
n/a
n/a
-CA$15m
Oct 31 2025
n/a
n/a
-CA$14m
Jul 31 2025
n/a
n/a
-CA$11m
Apr 30 2025
CA$82k
CA$82k
-CA$8m
Compensation vs Market: Thomas's total compensation ($USD58.15K) is below average for companies of similar size in the US market ($USD658.93K).
Compensation vs Earnings: Insufficient data to compare Thomas's compensation with company performance.
CEO
Thomas O’Shaughnessy (48 yo)
2yrs
Tenure
CA$82,000
Compensation
Mr. Thomas O’Shaughnessy is Chief Executive Officer of Onco-Innovations Limited since July 12, 2024. Mr. O’Shaughnessy was President of Healthtech at Nordic Consulting Partners, Inc from Dec 2022 to Dec 20...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Thomas O’Shaughnessy
Chief Executive Officer
2yrs
CA$82.00k
0.13% $ 36.8k
David Antony
CFO & Corporate Secretary
less than a year
no data
no data
Stephen Novak
Chief of Research & Development
less than a year
no data
no data
Islam Mohamed
Chairman of Scientific
less than a year
no data
0.49% $ 141.9k
Fadia Saad
Consultant
no data
no data
no data
Frederick West
Technology Transfer Advisor
no data
no data
no data
0.3yrs
Average Tenure
62yo
Average Age
Experienced Management: ONNV.F's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
Name
Position
Tenure
Compensation
Ownership
Islam Mohamed
Chairman of Scientific
1yr
no data
0.49% $ 141.9k
Christopher Gulka
Director
less than a year
no data
0.050% $ 14.7k
Richard Heinzl
Independent Director
2yrs
CA$30.10k
0.33% $ 96.6k
Jared Rushton
Director
less than a year
no data
0.034% $ 9.8k
John Mackey
Member of Scientific & Clinical Advisory Board
less than a year
no data
no data
Maximilian Justus
Independent Director
2.3yrs
no data
0.029% $ 8.6k
Michael Weinfeld
Advisory Board Member
2yrs
no data
no data
James Orbinski
Member of Scientific & Clinical Advisory Board
1.3yrs
no data
no data
Steven Jones
Senior Scientific Advisor
1.2yrs
no data
no data
Dennis Hall
Member of Scientific & Clinical Advisory Board
1yr
no data
no data
Michael Lock
Member of the Scientific & Clinical Advisory Board
less than a year
no data
no data
1.0yrs
Average Tenure
50yo
Average Age
Experienced Board: ONNV.F's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/25 03:28
End of Day Share Price
2026/07/22 00:00
Earnings
2026/01/31
Annual Earnings
2025/04/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Onco-Innovations Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.